Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study

by Zacks Equity Research

Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -14.12% and -16.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Zacks Equity Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag

by Zacks Equity Research

Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.

Zacks Equity Research

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWO

Zacks Equity Research

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

by Zacks Equity Research

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Zacks Equity Research

Editas (EDIT) Down on Initial Data From Eye Disease Study

by Zacks Equity Research

Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.

Zacks Equity Research

New Strong Sell Stocks for August 24th

by Zacks Equity Research

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021